Rocket Pharmaceuticals, Inc. (RCKT)
RCKT Stock Price Chart
Explore Rocket Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RCKT price movements and trends.
RCKT Company Profile
Discover essential business fundamentals and corporate details for Rocket Pharmaceuticals, Inc. (RCKT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Feb 2015
Employees
299.00
Website
https://rocketpharma.comCEO
Gaurav D. Shah
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
RCKT Financial Timeline
Browse a chronological timeline of Rocket Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.48, while revenue estimate is $326.78K.
Earnings released on 7 Aug 2025
EPS came in at -$0.59 falling short of the estimated -$0.57 by -3.51%.
Earnings released on 8 May 2025
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%.
Earnings released on 27 Feb 2025
EPS came in at -$0.62 surpassing the estimated -$0.68 by +8.82%.
Earnings released on 7 Nov 2024
EPS came in at -$0.71 surpassing the estimated -$0.78 by +8.97%.
Earnings released on 5 Aug 2024
EPS came in at -$0.74 matching the estimated -$0.74.
Earnings released on 6 May 2024
EPS came in at -$0.66 surpassing the estimated -$0.69 by +4.35%.
Earnings released on 26 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.80 by +20.00%, while revenue for the quarter reached $10.31M .
Earnings released on 6 Nov 2023
EPS came in at -$0.75 surpassing the estimated -$0.82 by +8.54%.
Earnings released on 10 Aug 2023
EPS came in at -$0.82 falling short of the estimated -$0.80 by -2.50%.
Earnings released on 4 May 2023
EPS came in at -$0.73 surpassing the estimated -$0.86 by +15.12%.
Earnings released on 27 Feb 2023
EPS came in at -$0.92 falling short of the estimated -$0.81 by -13.58%.
Earnings released on 3 Nov 2022
EPS came in at -$0.87 falling short of the estimated -$0.77 by -12.99%.
Earnings released on 8 Aug 2022
EPS came in at -$0.83 falling short of the estimated -$0.68 by -22.06%.
Earnings released on 5 May 2022
EPS came in at -$0.67 surpassing the estimated -$0.70 by +4.29%.
Earnings released on 24 Feb 2022
EPS came in at -$0.69 surpassing the estimated -$0.75 by +8.00%.
Earnings released on 3 Nov 2021
EPS came in at -$0.79 falling short of the estimated -$0.58 by -36.21%.
Earnings released on 9 Aug 2021
EPS came in at -$0.55 surpassing the estimated -$0.66 by +16.67%.
Earnings released on 10 May 2021
EPS came in at -$0.65 surpassing the estimated -$0.77 by +15.58%.
Earnings released on 25 Feb 2021
EPS came in at -$1.08 falling short of the estimated -$0.52 by -107.69%.
Earnings released on 4 Nov 2020
EPS came in at -$0.53 falling short of the estimated -$0.46 by -15.22%.
RCKT Stock Performance
Access detailed RCKT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.